Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio
Biogen, Inc. (NQ: BIIB)
300.26 USD  +0.87 (+0.29%)
Official Closing Price  /  Updated: 7:54 PM EST, Dec 6, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 2,261,300
Open 299.68
Bid (Size) 300.21 (1)
Ask (Size) 301.00 (1)
Prev. Close 299.39
Today's Range 299.68 - 304.56
52wk Range 215.77 - 344.00
Shares Outstanding 211,007,945
Dividend Yield N/A
Performance
YTD
-1.45%
-1.45%
1 Month
+4.67%
+4.67%
3 Month
+30.55%
+30.55%
6 Month
+31.46%
+31.46%
1 Year
-5.20%
-5.20%
Top News
More News
Notable Friday Option Activity: SFIX, BIIB, UNFI
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Stitch Fix Inc (SFIX), where a total of 14,636 contracts have traded so far, representing... Read More
category Stocks
from Market News Video
PJP, MDCO, LLY, BIIB: ETF Inflow Alert
Symbols mentioned in this story: PJP, MDCO, LLY, BIIB Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units''... Read More
category ETFs
from ETF Channel
More News
Read More
Alzheimer’s expert says more clinical trials are needed for controversial Biogen drug
category BIIB , General , JP:4523 , and 3 more.
from MarketWatch
Why Biogen’s Alzheimer’s Drug Presentation Left Investors Uninspired
category Market News , BIIB
from Motley Fool
UPDATE 2-Biohaven Pharma to continue late-stage study of Alzheimer's treatment
category companyNews
from Reuters: Company News
Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation
category alzheimer's , Market News , Alethia Young , and 14 more.
from Benzinga
Will The FDA Approve Biogen's Controversial Alzheimer's Drug?
from Investor's Business Daily
UPDATE 1-Biohaven Pharma to continue late-stage study of Alzheimer's treatment
category companyNews
from Reuters: Company News
Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response
category Trading Ideas , Alethia Young , Analyst Color , and 13 more.
from Benzinga
Stocks Are Set To Soar On Huge Employment Report Beat
category Stocks / Equities
from Blogs - TalkMarkets
Mike Khouw Highlights Unusual Options Activity In Biogen
category Options Action , Mike Khouw , BIIB , and 6 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.